Tempest Therapeutics Inc. (TPST)

NasdaqCM: TPST · Real-Time Price · USD

1.07

+0.00 (0.00%)

At close: Aug 19, 2026, 8:00 PM

1.07

+0.00%

After-hours: 4:10 PM

0.00% (1D)

No data available

Bid	0.76
Market Cap	17.1M
Revenue (ttm)	n/a
Net Income (ttm)	-40.47M
Beta	n/a
EPS (ttm)	-3.68
PE Ratio (ttm)	n/a
Forward PE	-0.88
P/B (ttm)	18.77
P/S (ttm)	n/a
Earnings Date	Nov 5, 2026

Ask	1.33
Volume	147,970
Avg. Volume (20D)	210,251
Open	1.02
Previous Close	1.07
Day's Range	1.02 - 1.08
52-Week Range	0.84 - 12.23
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About TPST

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 12, 2012

Employees 4

Stock Exchange NasdaqCM

Ticker Symbol TPST

Website https://www.tempesttx.com

Full Company Profile

Financial Performance

In 2025, Tempest Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -26.26M, a decrease of -37.24%.

Financial Statements